Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cardinal Health Inc (CAH) vs Ferrari NV (RACE) Price & Performance

Cardinal Health IncTrade
Ferrari NVTrade

Price performance (Past 24H)

Key statistics

Cardinal Health Inc vs Ferrari NV — how do they compare? Cardinal Health Inc trades at $236.63 (market cap $55.88B), while Ferrari NV trades at $406.53 (market cap $71.67B). The key difference: Ferrari NV is the larger of the two by market cap, and Ferrari NV pays the higher dividend (1.04%). Which is the better fit depends on your goals.

CAHRACE
Market Cap
$55.88B$71.67B
Sector
HealthConsumer Cyclical
52-Week High
$240.26$504.09
52-Week Low
$146.04$314.63
Enterprise Value
$59.91B$73.60B
Dividend Yield
0.86%1.04%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cardinal Health Inc

Cardinal Health (CAH) trades at $236.87, down 0.13% on the day, near its 52-week high. The stock shows strong momentum with four consecutive quarterly EPS beats, including Q2 2026 EPS of $2.91 versus $2.42 expected. Technical indicators are bullish overall, with moving averages supporting upward trends. Revenue reached $222.58 billion in 2025, with net income margin improving to 0.67%.

Outlook remains positive driven by robust pharmaceutical demand and optimistic FY2027 guidance. Key risks include high debt levels and thin profit margins. Analysts maintain a bullish consensus with a $266.43 price target, representing 12.5% upside. The stock presents a growth opportunity but requires monitoring of margin pressures and cash flow volatility.

Ferrari NV

Ferrari (RACE) trades at $405.73, down 0.26% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported Q2 2026 EPS of $2.99, beating estimates of $2.83, and raised full-year guidance, driven by robust personalization demand and pricing power. Revenue growth has been consistent, reaching $7.15B in 2025, with a net income margin of 22.25% and high profitability metrics like a 45.45% ROE.

The outlook remains positive given strong order books, margin expansion, and analyst consensus favoring a buy rating with a $462.67 price target. Key risks include premium valuation multiples limiting upside and sensitivity to luxury demand cycles. The stock's proximity to its 52-week high suggests momentum but warrants caution on overextension.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Cardinal Health Inc

Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.

Read more on CAH

About Ferrari NV

Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.

Read more on RACE